Crossmark

Health-related Quality of Life Outcomes of Adalimumab for Patients With Rheumatoid Arthritis in Korea

Crossref DOI link: https://doi.org/10.4078/jrd.2021.28.2.68

Published Print: 2021-04-01

Update policy: https://doi.org/10.4078/crossmark_policy

Authors

Lee, Myeung-su

Lee, Chang Hoon

Lee, Hye Soon

Sung, Yoon-Kyoung

Choi, Jung Ran

Park, Kyungsu

Lim, Mi-Kyoung

Choi, Byoong Yong

Kim, Hyoun-Ah

Choi, Seung Won

Lee, Yusun

Yoo, Wan-Hee https://orcid.org/0000-0002-8430-7629
Funding

Funding for this research was provided by:

AbbVie (P15-777)
License Information

Text and Data Mining valid from 2021-04-01
More Information

Full text available at:

J Rheum Dis: http://www.jrd.or.kr/journal/view.html?doi=10.4078/jrd.2021.28.2.68

Publication History

Received: 2020-06-29

Revised: 2020-11-26

Accepted: 2020-11-26

Published: 2021-04-01

ORCID

Wan-Hee Yoo: https://orcid.org/0000-0002-8430-7629

Copyright and Licensing

Copyright: © 2021 The Korean College of Rheumatology

License: This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.